Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Ch... (rald DonowitzM.D. will feature presentat...)

HOME >> MEDICINE >> TECHNOLOGY

Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy

Date:9/5/2007

rald Donowitz, M.D., will feature presentations by Richard Wunderink, M.D., Joseph Blondeau, Ph.D. and B. Joseph Guglielmo, Jr., Pharm.D., all thought leaders in the field of infectious disease and microbiology. The satellite symposium is supported by Advanced Life Sciences through an unrestricted educational grant to the American Society for Microbiology and Conexus Health.

Symposium and Presentation Schedule

Monday, September 17, 7:00 p.m. Central Daylight Time, Room E354A

-- Satellite Symposium: Drug Resistant CAP, Current and Future Treatments:

Best Practices for Prevention and Management

Tuesday, September 18, 11:15 a.m. Central Daylight Time, Room E253D

Poster Session 222: Pathogenesis and Therapeutics in Agents of

Bioterrorism

-- Poster: Poster B-2031: Efficacy of Cethromycin Against a Lethal

Inhalation Anthrax Challenge in Rhesus Macaques

Wednesday, September 19, 12:15 p.m. Central Daylight Time, Hall D

Poster Session 176: Macrolides, Ketolides, Bicyclolides and Quinolones

-- Poster E-1633: Assessment of In Vitro Activity of Cethromycin Against

Telithromycin-resistant Strains of Streptococcus pneumoniae

-- Poster E-1632: Assessment of In Vitro Activity of Cethromycin Against

Strains of Streptococcus pneumoniae

-- Poster E-1631: Assessment of In Vitro Activity of Cethromycin Against

Strains of Haemophilus influenzae

-- Poster E1634: Antimicrobial Activity of Cethromycin, a Novel Ketolide,

Tested against a Diverse Collection of Francisella tularensis Strains

Thursday, September 20, 9:00 a.m. Central Daylight Time, Hall D

Poster Session 82: New Drug Pharmacokinetics

-- Poster A-797: Evaluation of the Safety and Pharmacokinetics of

Cethromycin Following Administration of Multiple Doses to Subjects with

Severe Renal Impairment

-- Poster A-796: Evaluation of the Safety and Pharmacokinetics
'/>"/>

0

GOOD

Page: 1 2 3 4
Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
3. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
4. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
5. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
6. Progenics and Wyeth Announce Positive Results from Three-Month Clinical-Extension Study of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness
7. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
8. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
9. Advanced Viral Research Corp. Announces Positive Preliminary Findings from Ongoing Phase II Dermatological Study
10. Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors
11. Updated Study Results Reinforce Survival Benefit of Taxotere (Docetaxel) for Men with Advanced, Hormone-Resistant Prostate Cancer

Post Your Comments:

Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Ch...(rald DonowitzM.D. will feature presentat...),Health